[Detection of tumor cells in bone marrow: a deciding aid for adjuvant therapy in node negative patients with breast cancer. Concept for a multicenter study and results of the pilot phase].
In node-negative breast cancer some 30% of patients will suffer a tumor relapse, despite primary curative therapeutic intervention. An adjuvant therapy is therefore in discussion, especially in presence of risk factors. Immunocytochemical staining of cytokeratin-positive cells in bone marrow aspirates with monoclonal antibodies offers a chance to detect tumorcell dissemination at an early stage of single tumor cells. In 103 consecutive patients 50% showed a positive bone marrow aspirate, in node negative patients still 34%. Based on the literature and tumor biology this method may be valid in selecting node-negative breast cancer patients for adjuvant therapy. In a prospective multi-center trial the prognostic value will be evaluated in regard to other prognostic factors. Additionally the benefit of an adjuvant therapy will be studied in a randomized prospective trial.
Funke
I
I
Chirurgische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, Klinikum Grosshadern.
Fries
S
S
Jauch
K W
KW
D014408:Biomarkers, Tumor / Q000032:analysis; D001707:Biopsy, Needle; D001853:Bone Marrow / Q000473:pathology*; D001859:Bone Neoplasms / Q000473:pathology* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology* / Q000601:surgery*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D011446:Prospective Studies
D014408:Biomarkers, Tumor
Tumorzellnachweis im Knochenmark: Entscheidungshilfe zur adjuvanten Therapie bei nodal-negativen Patientinnen mit Mammacarcinom. Konzept einer Multicenterstudie und Ergebnisse der Pilotphase.